Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

68
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
68
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

119
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
119
Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Biomarker-enhanced Cardiovascular Risk Prediction In Patients With Cancer: A Prospective Cohort Study

Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study

Simon Kraler1, Luca Liberale2, Stephan Nopp3

  • 1Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland; Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland. Electronic address: https://twitter.com/KralerSimon.

Journal of Thrombosis and Haemostasis : JTH
|September 2, 2024

Related Experiment Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

229

View abstract on PubMed

Summary
This summary is machine-generated.

Improving cancer survival increases cardiovascular risk. A new risk score using biomarkers like ICAM-1 and NT-proBNP helps identify cancer patients at high risk for major adverse cardiovascular events (MACE) and cardiovascular death.

Keywords:
C-reactive proteinN-terminal pro-BNPcardio-oncologycardiovascular biomarkers

Related Experiment Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

229

Area of Science:

  • Cardiology
  • Oncology
  • Biomarker Discovery

Background:

  • Improving cancer survival leads to increased risk of major adverse cardiovascular events (MACE).
  • Current cardiovascular risk prediction tools are not tailored for cancer patients.
  • There is a need for specialized risk assessment in oncology settings.

Purpose of the Study:

  • To evaluate a comprehensive panel of cardiovascular biomarkers and risk factors.
  • To predict major adverse cardiovascular events (MACE) and cardiovascular death in cancer patients.
  • To develop a novel risk prediction model for cardiovascular outcomes in cancer.

Main Methods:

  • Prospective follow-up of 2192 cancer patients for 2-year MACE and 5-year cardiovascular death.
  • Analysis of traditional risk factors and specific biomarkers (ICAM-1, NT-proBNP, selectins).
  • Development and validation of clinical and biomarker-enhanced risk scores.

Main Results:

  • Traditional factors and cancer type influenced MACE risk.
  • ICAM-1, P-/E-/L-selectins, and NT-proBNP independently predicted 2-year MACE.
  • A clinical risk score achieved a C-statistic of 0.76; biomarker enhancement improved prediction to 0.83.
  • Biomarker models showed C-statistics of 0.82 and 0.74 for 5-year cardiovascular death.

Conclusions:

  • Biomarker-enhanced risk prediction effectively identifies cancer patients at high risk for MACE and cardiovascular death.
  • A novel risk score shows promise for personalized cardiovascular risk assessment in cancer patients.
  • External validation is ongoing to confirm the utility of this risk stratification tool.
growth differentiation factor 15
inflammation
lipoprotein(a)
major adverse cardiovascular events
personalized risk assessment
precision medicine
prevention